Screener
Ultragenyx Pharmaceutical RARE Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Ultragenyx Pharmaceutical’s reported figures.
Based on the most recent quarter.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed November 5, 2025. Open the filing →
- Filed
- Nov 5, 2025
- Fiscal quarter
- Q3 FY2025
- Calendar quarter
- Q3 2025
- Accession
- 0001193125-25-265126
FAQ
- What is Ultragenyx Pharmaceutical's debt-to-equity?
- Ultragenyx Pharmaceutical (RARE) reported debt-to-equity of 3.7× in Q3 2025.
- What is the long-term trend for Ultragenyx Pharmaceutical's debt-to-equity?
- Over 4 years (2020 to 2024), Ultragenyx Pharmaceutical's debt-to-equity has grown at a 39.5% compound annual growth rate (CAGR), from 0× to 0.2×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Ultragenyx Pharmaceutical's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude